DESCAR-T is the French national registry for patients treated with commercial chimeric antigen receptor (CAR)-T cells across all haematological malignancies aimed to collect real-world data including safety and effectiveness up to 15 years after CAR-T cell infusion.
Several complementary registries are also linked to the DESCAR-T database such as an immune-monitoring database, a blood and tumour biobank, and an imagery platform.
In this study, the aim was to analyse patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.
The results of this study were presented by Professor Steven Le Gouill in an oral session at the EHA 2021 virtual congress.
Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy.
Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused.
The median time from CAR-T order to infusion was 50 days.
Of the patients who completed CAR-T therapy, 350 patients were infused with Axi-cel and 200 received Tisa-acel.
Analysing the response data from 460 infused patients, it was found that 40 % achieved complete remission and 30% achieved partial remission by Day 30.
The progression-free survival at 6 months calculated from the time of CAR- T infusion was 44.5% [39.6-49.2] months.
In conclusion, the analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.